AVELOX as effective as multi-dose combination therapy for intra-abdominal infections

Schering-Plough Corporation (NYSE: SGP) today reported that monotherapy with the once-daily, broad-spectrum antibiotic AVELOX (moxifloxacin HCl) was as effective and well tolerated as a standard multi-dose combination antibiotic regimen in the treatment of patients with complicated intra-abdominal infections (cIAI), according to results of a study involving 681 patients published in the current issue of the Annals of Surgery.(1) AVELOX, the only marketed fluoroquinolone antibiotic approved by the U.S. Food and Drug Administration (FDA) as monotherapy to treat cIAI, was shown to be effective at eradicating the most common bacteria that cause cIAI, including E. coli and B. fragilis.

In the study, patients who took 400 mg once daily of AVELOX intravenous (I.V.) followed by oral monotherapy achieved similar clinical cure rates (80 percent) at the test-of-cure visit (the primary efficacy endpoint) as patients who took a standard regimen of I.V. piperacillin-tazobactam followed by oral amoxicillin-clavulanate (78 percent).

Importantly, AVELOX demonstrated a significantly higher cure rate of 82 percent compared to 55 percent for the combination therapy among patients who acquired their cIAI in a hospital setting (including both mild-to-moderate and more severe hospital-acquired infections). Hospital-acquired infections are often caused by more resistant bacteria than community-acquired infections. Clinical cure rates for patients with community-acquired infections were similar between the two treatment groups.

The incidence of adverse events in the study due to any cause was similar for the two treatment groups, with the majority being mild or moderate in nature. The most common adverse events were nausea, hypokalemia, abdominal pain and constipation. The incidence of drug-related serious adverse events or premature discontinuation due to adverse events was similar for the two treatment groups.

"The results of this study are


Page: 1 2 3

Related biology news :

1. FDA approves AVELOX (moxifloxacin HCl) for treatment of complicated intra-abdominal infections
2. Smokeless tobacco more effective than cigarettes for delivering dangerous carcinogens into the body
3. Developing a more effective vaccine for tuberculosis
4. Cost-effective method for gene silencing is featured in Cold Spring Harbor Protocols
5. Implanon, Norplant and Jadelle are all effective contraceptives -- but side effects vary
6. High blood pressure medication strategy proves effective in Hispanic women
7. New compound effectively treats fungal infections
8. Northern forests less effective than tropical forests in reducing global warming
9. Cisplatin is more effective than carboplatin for treating nonsmall cell lung cancer
10. Scientists develop new drugs to fight colon and breast cancer more effectively
11. Avian influenza survivors antibodies effective at neutralising H5N1 strain

Post Your Comments:
(Date:9/10/2015)... 2015 Pursuant Health has collaborated with ... an interactive, image-based health risk assessment (HRA) optimized ... The unique assessment quantifies user results into an ... an individual,s biological age based on personal health ... the kiosk. Comprised of age, gender, ...
(Date:9/8/2015)... , Sept. 8, 2015   TREW Marketing ... new survey, Smart Marketing for Engineers TM : ... engineering professionals reveals insightful findings about engineers, preferences for ... of content engineers most value and trust, and where ... Marketers targeting technical audiences grapple with how to best ...
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015 /PRNewswire/ ... a key concern for enterprises, banks, government organizations, ... badges, and numeric keypads were previously being used ... the introduction of two-factor authentication, wherein individuals could ... using two different components, such as hardware devices ...
Breaking Biology News(10 mins):
(Date:10/8/2015)... 2015 Global Biologics and ... and Biosimilars industry . --> Big ... Biosimilars Industry 2015 Deep Market Research Report, Size, ... professional and depth research report on Global ... ) , --> http://photos.prnewswire.com/prnh/20141014/710132 ) , ...
(Date:10/8/2015)... -- The ALS Association, in partnership with Prize4Life, is pleased ... communication technology solutions for people living with ALS. ... lateral sclerosis) is a progressive neurodegenerative disease that affects ... cord. Eventually, people with ALS lose the ability to ... total paralysis and death within two to five years ...
(Date:10/8/2015)... , Oct. 8, 2015  Sigma-Aldrich Corporation (NASDAQ: ... ® brand within its Applied Diagnostics and ... acid reference standards product line with ten certified ... tested bile acids and their stable-labeled internal standards. ... of lithocholic acid, taurocholic acid and native and ...
(Date:10/8/2015)... ... October 08, 2015 , ... Cystic ... transmembrane conductance regulator (CFTR) gene and results in dysfunction of the lungs and ... in the lungs. This mucus is very difficult to clear, blocks the airways ...
Breaking Biology Technology:
Cached News: